Welcome to our dedicated page for AC Immune SA news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune SA stock.
AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, committed to pioneering precision medicine for neurodegenerative diseases. The company specializes in designing, discovering, and developing innovative therapeutic and diagnostic products aimed at preventing and modifying diseases caused by misfolded proteins. Utilizing its two proprietary technology platforms, SupraAntigen® and Morphomer®, AC Immune develops a broad spectrum of antibodies, small molecules, and vaccines targeting conditions such as Alzheimer’s disease (AD), Parkinson’s disease, and NeuroOrphan indications.
With a robust pipeline consisting of sixteen therapeutic and diagnostic programs, AC Immune currently has six product candidates in clinical trials, including five in Phase 2 and one in Phase 3. The most advanced candidate, Crenezumab, is a humanized anti-amyloid-β monoclonal antibody in Phase 3 trials aimed at treating Alzheimer’s disease. Other notable candidates include ACI-24.060, a promising anti-Abeta active immunotherapy for AD and Down syndrome, which has received FDA Fast Track Designation, and ACI-35.030, an anti-pTau active immunotherapy in Phase 2b trials for preclinical AD conducted by Janssen Pharmaceuticals.
Beyond its rich pipeline, AC Immune is known for its strategic partnerships with leading global pharmaceutical companies such as Genentech (a Roche Group member), Eli Lilly and Company, and Takeda. These collaborations have resulted in significant non-dilutive funding and milestone payments totaling over $4.5 billion.
AC Immune recently secured an exclusive option and license agreement with Takeda for its ACI-24.060 product, potentially worth $2.1 billion, and completed a $50 million equity financing to support its operations into 2026. The company's focused efforts on precision prevention are reinforced by its ongoing Phase 2 trials and collaborations aimed at leveraging advanced diagnostic techniques like PET imaging and novel therapeutic approaches for early and effective intervention in neurodegenerative diseases.
AC Immune (NASDAQ: ACIU) received a USD 600,000 grant from Target ALS to advance a collaboration with Massachusetts General Hospital. The funding will accelerate the development of proprietary immuno-assays for detecting TDP-43, a protein linked to several neurodegenerative diseases, including ALS. These assays aim to improve early diagnostics, enabling targeted treatment strategies. AC Immune's CEO highlighted the potential of these assays and the ongoing development of an anti-TDP-43 therapeutic antibody. This positions the company as a leader in precision medicine for neurodegenerative conditions.
AC Immune has announced the appointment of Prof. June as a scientific leader, reinforcing the company's expertise in neurodegeneration. Prof. June is recognized globally for his work in immune tolerance and adoptive immunotherapy. This leadership change aligns with AC Immune's strategy to enhance its research capabilities, particularly in neurodegenerative diseases. The company is expected to leverage his knowledge to advance its pipeline and foster innovation.
AC Immune announces the appointment of Prof. Johannes R. Streffer as Chief Medical Officer, effective January 2021. With extensive experience in neurology and psychiatry, Prof. Streffer aims to enhance AC Immune's pipeline targeting neurodegenerative diseases. Previously at UCB Biopharma, he led advancements in neuroscience and clinical study design, particularly in Alzheimer’s disease. The company’s pipeline includes nine therapeutic candidates, with collaborations involving major pharmaceutical firms like Genentech and Eli Lilly.
AC Immune SA (NASDAQ: ACIU) reported Q3 2020 financial results, achieving revenues of CHF 1.1 million amid a significant decline of CHF 32.1 million year-over-year. The company holds CHF 246.6 million in cash, funding operations until Q1 2024. A Phase 1 trial with Eli Lilly for Morphomer™ Tau showed promising pharmacokinetics, while the TDP-43 therapeutic program advances with EU grant support. However, a Phase 2 trial of the anti-Tau antibody did not meet primary efficacy endpoints. R&D expenditures increased by over 35%, and the net loss for Q3 reached CHF 19 million.
AC Immune (NASDAQ: ACIU), a leading biopharmaceutical company focused on neurodegenerative diseases, announced its participation in the Jefferies Virtual London Healthcare Conference on November 18, 2020. CEO Prof. Andrea Pfeifer will discuss the company’s strategies for 2021, particularly its candidates targeting TAR DNA-binding protein 43 (TDP-43), which is critical in conditions like Alzheimer’s and amyotrophic lateral sclerosis (ALS). The presentation aims to highlight their innovative approach to precision medicine in treating these diseases.
AC Immune SA has entered a strategic partnership with WuXi Biologics to advance its TDP-43 antibody into clinical development for NeuroOrphan indications. This agreement leverages AC Immune's drug discovery platforms and WuXi's manufacturing capabilities to address the significant unmet medical needs related to TDP-43-related neurodegenerative diseases. The collaboration aims to expedite the drug development process, with AC Immune retaining all intellectual property rights. This partnership highlights the company's growth and commitment to bringing innovative treatments to market.
AC Immune (NASDAQ: ACIU) has secured a €1.45M grant from the EU's Joint Programme – Neurodegenerative Disease Research (JPND). This funding will support the development of the first-in-class TDP-43 PET tracer in collaboration with the JPND ImageTDP-43 consortium, aimed at detecting neurodegenerative diseases including ALS and FTLD-TDP. The company emphasizes its innovative Morphomer™ platform's role in advancing precision medicine, as highlighted by CEO Prof. Andrea Pfeifer. The TDP-43 PET tracer shows strong binding to pathological aggregates, enhancing diagnostics and potential treatments for Alzheimer’s disease.
AC Immune (NASDAQ: ACIU) announced its participation in the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020. CEO Prof. Andrea Pfeifer will present the company’s advanced anti-Tau clinical pipeline, which includes an antibody, a small molecule inhibitor, and a vaccine targeting neurodegenerative diseases. The presentation will highlight recent results from their Tau PET imaging agent, PI-2620, which may aid in earlier diagnosis of progressive supranuclear palsy (PSP). Four clinical-stage assets are in development.
AC Immune SA (NASDAQ: ACIU) announced the start of investigational new drug (IND)-enabling studies for its first-in-class anti-TDP-43 antibody, which is the only antibody reported to have in vivo activity against TDP-43 neuropathology. This antibody targets various neurodegenerative conditions, including ALS and FTLD-TDP, associated with significant market potential. The initiative follows several key achievements in the company’s pipeline, which utilizes the proprietary SupraAntigen™ and Morphomer™ platforms. CEO Andrea Pfeifer emphasized the importance of this milestone in addressing unmet needs in neurodegenerative diseases.
FAQ
What is the current stock price of AC Immune SA (ACIU)?
What is the market cap of AC Immune SA (ACIU)?
What is AC Immune's primary focus?
What are AC Immune's most advanced product candidates?
What technology platforms does AC Immune use?
Who are AC Immune's strategic partners?
What is the significance of the recent agreement with Takeda?
How is AC Immune funded?
What is AC Immune’s financial outlook?
What ongoing clinical trials is AC Immune conducting?
What recent milestones has AC Immune achieved?
How does AC Immune contribute to the field of neurodegenerative disease research?
